NCT05187624View on ClinicalTrials.gov

A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

May 14, 2025

Study Completion Date

May 14, 2025

Conditions
Glioblastoma
Interventions
DRUG

RO7428731

Participants will receive RO7428731 as described.

Trial Locations (8)

2100

Rigshospitalet, Onkologisk Klinik, København Ø

3000

Peter MacCallum Cancer Centre, Melbourne

10065

Memorial Sloan Kettering Cancer Center, New York

28027

Clinica Universidad de Navarra Madrid, Madrid

31008

Clinica Universitaria de Navarra, Pamplona

90095

UCLA Neuro-Oncology Program, Los Angeles

M5G 1Z5

Princess Margaret Cancer Center, Toronto

08035

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY